BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts

Reuters

Feb 06

BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts

Updates

** Neuren Pharmaceuticals NEU.AX slips 3.41% to A$12.750, heading toward a tenth straight day of losses

** Stock slids 22.9% so far this week and is on track for its weakest weekly showing in over 11 weeks

** Jefferies trims PT and annual earnings forecasts for NEU after setback for Rett treatment drug application from European regulator

** NEU on Tuesday said licensee Acadia Pharmaceuticals ACAD.O has reported that a committee of the European Medicines Agency issued a negative trend vote on its marketing-authorisation application for the trofinetide drug

** Jefferies says following the latest setback, it now assumes EU trofinetide royalties will begin in Q4 rather than Q2, cutting NEU's FY26 NPAT forecast to A$48.1 million ($33.48 million) from A$58.2 million

** Trims its price target to A$27 from A$27.75, maintains "Buy" rating

** Stock down 31.5% YTD

($1 = 1.4366 Australian dollars)

(Reporting by Kumar Tanishk in Bengaluru)

((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609533926"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609533926\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609533926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 07:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609533926","market":"nz","top_or_hot":-1,"title":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts</title></head><body><p>Updates</p><p>** <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> <span>NEU.AX</span> slips 3.41% to A$12.750, heading toward a tenth straight day of losses</p><p>** Stock slids 22.9% so far this week and is on track for its weakest weekly showing in over 11 weeks</p><p>** Jefferies trims PT and annual earnings forecasts for NEU after setback for Rett treatment drug application from European regulator</p><p>** NEU on Tuesday <span>said </span>licensee Acadia Pharmaceuticals <span>ACAD.O</span> has reported that a committee of the European Medicines Agency issued a negative trend vote on its marketing-authorisation application for the trofinetide drug</p><p>** Jefferies says following the latest setback, it now assumes EU trofinetide royalties will begin in Q4 rather than <a href=\"https://laohu8.com/S/QTWO\">Q2</a>, cutting NEU's FY26 NPAT forecast to A$48.1 million ($33.48 million) from A$58.2 million</p><p>** Trims its price target to A$27 from A$27.75, maintains \"Buy\" rating</p><p>** Stock down 31.5% YTD</p><p>($1 = 1.4366 Australian dollars)</p><p>(Reporting by Kumar Tanishk in Bengaluru)</p><p>((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 07:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts</title></head><body><p>Updates</p><p>** <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> <span>NEU.AX</span> slips 3.41% to A$12.750, heading toward a tenth straight day of losses</p><p>** Stock slids 22.9% so far this week and is on track for its weakest weekly showing in over 11 weeks</p><p>** Jefferies trims PT and annual earnings forecasts for NEU after setback for Rett treatment drug application from European regulator</p><p>** NEU on Tuesday <span>said </span>licensee Acadia Pharmaceuticals <span>ACAD.O</span> has reported that a committee of the European Medicines Agency issued a negative trend vote on its marketing-authorisation application for the trofinetide drug</p><p>** Jefferies says following the latest setback, it now assumes EU trofinetide royalties will begin in Q4 rather than <a href=\"https://laohu8.com/S/QTWO\">Q2</a>, cutting NEU's FY26 NPAT forecast to A$48.1 million ($33.48 million) from A$58.2 million</p><p>** Trims its price target to A$27 from A$27.75, maintains \"Buy\" rating</p><p>** Stock down 31.5% YTD</p><p>($1 = 1.4366 Australian dollars)</p><p>(Reporting by Kumar Tanishk in Bengaluru)</p><p>((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065170008.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL6N3Z11HG:1","article_id":"2609533926","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609533926","pubTimestamp":1770334764,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cutsUpdates** Neuren Pharmaceuticals NEU.AX slips 3.41% to A$12.750, heading toward a tenth straight day of losses** St","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK7096":"制药","JEF":"杰富瑞","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK4139":"生物科技","BK4127":"投资银行业与经纪业","ACAD":"阿卡迪亚","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK7508":"医药生物股","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4559":"巴菲特持仓"},"translate_title":"BUZZ-澳大利亚Neuren股价下跌，Rett药物受挫促使Jefferies PT下调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JEF":0.9,"ACAD":0.9,"NEU.AU":0.9},"content_text":"BUZZ-Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cutsUpdates** Neuren Pharmaceuticals NEU.AX slips 3.41% to A$12.750, heading toward a tenth straight day of losses** Stock slids 22.9% so far this week and is on track for its weakest weekly showing in over 11 weeks** Jefferies trims PT and annual earnings forecasts for NEU after setback for Rett treatment drug application from European regulator** NEU on Tuesday said licensee Acadia Pharmaceuticals ACAD.O has reported that a committee of the European Medicines Agency issued a negative trend vote on its marketing-authorisation application for the trofinetide drug** Jefferies says following the latest setback, it now assumes EU trofinetide royalties will begin in Q4 rather than Q2, cutting NEU's FY26 NPAT forecast to A$48.1 million ($33.48 million) from A$58.2 million** Trims its price target to A$27 from A$27.75, maintains \"Buy\" rating** Stock down 31.5% YTD($1 = 1.4366 Australian dollars)(Reporting by Kumar Tanishk in Bengaluru)((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}